img 20261106 wa8096

Cancer Drug Prices Drop Further: How Will Capping Commercial Margins Benefit Patients?

Commercial margins for 137 cancer drugs have been capped, limiting the markup over the procurement price relative to the Maximum Retail Price (MRP).

New Delhi, November 6, 2026

Prices of cancer drugs have decreased by an average of 20% to 70%.

To reduce the cost of cancer treatment in the country, the government has imposed a cap on excessive profit margins across various stages of the pharmaceutical supply chain, including retail outlets and hospital pharmacies. Pharmaceutical manufacturers have reported an average reduction of 20% to 70% in the Maximum Retail Price (MRP). The maximum price reduction observed is 96.45% (as of November 4, 2026).

This reduction in MRP is estimated to result in savings of approximately ₹3,357.49 crore (as of November 4, 2026). This figure is calculated based on the difference between the previous prices and the revised prices, applied to the volume of drugs sold between April 2025 and March 2026. The move follows concerns raised by state authorities, patients, and civil society regarding the significant gap between the procurement cost of cancer drugs and their Maximum Retail Price (MRP).

Consumers can verify drug prices by visiting the NPPA (National Pharmaceutical Pricing Authority) website or using the government’s ‘Pharma Sahi Daam’ mobile app. The distributor price as of March 2026 has been used as the baseline for determining the new prices.

What is a commercial margin?

A commercial margin is the difference between the price at which a pharmaceutical manufacturer sells a drug to a stockist or distributor and the maximum price at which a patient purchases it. This margin is calculated excluding the Goods and Services Tax (GST). When commercial margins are excessively high, significant profits are added at every stage of the supply chain, which ultimately drives up the final price of the medication for patients. Cancer medications, which are already expensive, often end up costing patients significantly more than the prices set by the manufacturers.

How are drug prices regulated?

To make essential, life-saving medicines more affordable for patients, the government regulates drug prices under the Drugs (Prices Control) Order (DPCO), 2013.

This measure has been implemented under the Essential Commodities Act. Its objectives are to regulate drug prices, prevent excessive profiteering, and ensure that essential medical treatments remain affordable.

The DPCO 2013 categorizes medicines into two groups:

Scheduled medicines: This category includes drugs listed in the First Schedule of the DPCO 2013. This schedule is based on the National List of Essential Medicines (NLEM) 2022. The government sets a maximum price for each of these medicines. The NLEM 2022 includes a total of 388 medicines, 63 of which are for cancer.

Non-scheduled medicines: This category consists of medicines that are not included in the First Schedule of the DPCO 2013. Unlike scheduled medicines, these do not have a fixed maximum price. However, their prices are monitored. According to Paragraph 20 of the DPCO, a manufacturer cannot increase the maximum retail price (MRP) by more than 10 percent within a 12-month period. If a price increase exceeds 10 percent, the price must be reduced to bring it back within the 10 percent limit for the subsequent 12 months.

What is the National List of Essential Medicines (NLEM)?

The National List of Essential Medicines (NLEM) is the government’s official list of essential and priority medicines in India. Its latest revised version is the NLEM 2022. In line with the government’s vision of “Sabko Dawai, Sasti Dawai”—meaning “medicines for all at affordable prices”—this list was released by the Union Health Minister, Dr. Mansukh Mandaviya, on September 13, 2022.

History: The list was first created in 1996 and has since been revised in 2003, 2011, 2015, and 2022. Who prepares it: This list is compiled by experts from the Standing National Committee on Medicines (SNCM). It is prepared through consultations with physicians, scientists, and industry experts, while also taking into account the standards set by the World Health Organization (WHO).

Why this list is important:

Reducing medical costs: It helps alleviate the financial burden of healthcare on families.

Improving healthcare services: It ensures the safety, efficacy, and quality of medicines.

Assisting in planning: It provides a framework for government procurement of medicines, hospital budgeting, health insurance, and the training of medical students.

Legal basis for the mandate: Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013.

Special government powers: In exceptional circumstances, the government may take measures beyond standard regulations in the public interest.

Authority to set or adjust prices: The government has the power to fix or modify the maximum retail price (MRP) of any medicine as deemed necessary. Such prices can remain in effect for as long as the government deems appropriate.

Adjusting pre-existing prices: The government can directly increase or decrease the price of a medicine, even if it has been previously fixed. There is no need to wait for the routine annual price revision linked to the Wholesale Price Index (WPI).

How the cap on commercial margins for cancer drugs is determined under the new directive:

Commercial margin capped at 30% of the Maximum Retail Price (MRP): The margin—the difference between the price at which the manufacturer sells to a distributor and the price paid by the patient—cannot exceed 30%.

Applicable to all such medicines: This rule applies to all cancer drugs listed. It covers all forms and dosages (e.g., tablets, injections, etc.), whether sold individually or in combination with other medicines.

Leave a Reply

Your email address will not be published. Required fields are marked *